Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids

Walter T. Lee, Hidemasa Tamai, Peter A Cohen, Aysenur Meric Teker, Suyu Shu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC). Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2 K) mice. Subdermal tumors were established by inoculation in the mid abdomen of mice. Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy. Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors. Dendritic cells were generated from bone marrow and cultured for 8 days. Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse. Subjects: Female C3H/HEN mice aged 8 to 12 weeks. Interventions: Mice with 3-day established SCCVII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 × 106 per side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibodies or interleukin 12 were used. Treatment groups included no treatment, anti-OX40R monoclonal antibodies or adjuvant IL-12 alone, fusion cells alone, and fusion cells with adjuvant treatment. Main Outcome Measures: Tumor size and overall survival. Results: Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls. In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001). Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models. Conclusion: Immunotherapy with fused dendritictumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.

Original languageEnglish (US)
Pages (from-to)608-613
Number of pages6
JournalArchives of Otolaryngology - Head and Neck Surgery
Volume134
Issue number6
DOIs
StatePublished - Jun 2008
Externally publishedYes

Fingerprint

Immunotherapy
Dendritic Cells
Squamous Cell Carcinoma
Cell Fusion
Neoplasms
Interleukin-12
Therapeutics
Monoclonal Antibodies
Cultured Tumor Cells
Neoplasm Metastasis
Lung
Injections
Inbred C3H Mouse
Groin
Hybrid Cells
Growth
Abdomen
Immunity
Bone Marrow
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. / Lee, Walter T.; Tamai, Hidemasa; Cohen, Peter A; Teker, Aysenur Meric; Shu, Suyu.

In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 134, No. 6, 06.2008, p. 608-613.

Research output: Contribution to journalArticle

Lee, Walter T. ; Tamai, Hidemasa ; Cohen, Peter A ; Teker, Aysenur Meric ; Shu, Suyu. / Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. In: Archives of Otolaryngology - Head and Neck Surgery. 2008 ; Vol. 134, No. 6. pp. 608-613.
@article{eca0e877b1444fe2804819b8b8c0a0fc,
title = "Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids",
abstract = "Objective: To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC). Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2 K) mice. Subdermal tumors were established by inoculation in the mid abdomen of mice. Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy. Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors. Dendritic cells were generated from bone marrow and cultured for 8 days. Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse. Subjects: Female C3H/HEN mice aged 8 to 12 weeks. Interventions: Mice with 3-day established SCCVII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 × 106 per side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibodies or interleukin 12 were used. Treatment groups included no treatment, anti-OX40R monoclonal antibodies or adjuvant IL-12 alone, fusion cells alone, and fusion cells with adjuvant treatment. Main Outcome Measures: Tumor size and overall survival. Results: Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls. In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001). Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models. Conclusion: Immunotherapy with fused dendritictumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.",
author = "Lee, {Walter T.} and Hidemasa Tamai and Cohen, {Peter A} and Teker, {Aysenur Meric} and Suyu Shu",
year = "2008",
month = "6",
doi = "10.1001/archotol.134.6.608",
language = "English (US)",
volume = "134",
pages = "608--613",
journal = "JAMA Otolaryngology - Head and Neck Surgery",
issn = "2168-6181",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids

AU - Lee, Walter T.

AU - Tamai, Hidemasa

AU - Cohen, Peter A

AU - Teker, Aysenur Meric

AU - Shu, Suyu

PY - 2008/6

Y1 - 2008/6

N2 - Objective: To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC). Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2 K) mice. Subdermal tumors were established by inoculation in the mid abdomen of mice. Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy. Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors. Dendritic cells were generated from bone marrow and cultured for 8 days. Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse. Subjects: Female C3H/HEN mice aged 8 to 12 weeks. Interventions: Mice with 3-day established SCCVII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 × 106 per side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibodies or interleukin 12 were used. Treatment groups included no treatment, anti-OX40R monoclonal antibodies or adjuvant IL-12 alone, fusion cells alone, and fusion cells with adjuvant treatment. Main Outcome Measures: Tumor size and overall survival. Results: Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls. In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001). Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models. Conclusion: Immunotherapy with fused dendritictumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.

AB - Objective: To investigate the therapeutic efficacy of fused dendritic-tumor cell hybrids against murine squamous cell carcinoma (SCC). Design: Squamous cell carcinoma VII is a poorly immunogenic murine SCC tumor in C3H/HEN (H-2 K) mice. Subdermal tumors were established by inoculation in the mid abdomen of mice. Tumor diameters were measured with a Vernier caliper and used as an indication of treatment efficacy. Survival studies were performed on mice with 3-day pulmonary metastasis or subdermal tumors. Dendritic cells were generated from bone marrow and cultured for 8 days. Dendritic cells were harvested and mixed with cultured tumor cells in a 1:1 ratio. Cell fusion was achieved by exposing the cell mixture to an alternate electrical current to bring cells into alignment and close together, followed by a short direct electrical current pulse. Subjects: Female C3H/HEN mice aged 8 to 12 weeks. Interventions: Mice with 3-day established SCCVII tumors were vaccinated by inguinal intranodal injection of fusion cells (0.3 × 106 per side). To support the development of antitumor immunity, mice were given adjuvant injections intraperitoneally. Anti-OX40R monoclonal antibodies or interleukin 12 were used. Treatment groups included no treatment, anti-OX40R monoclonal antibodies or adjuvant IL-12 alone, fusion cells alone, and fusion cells with adjuvant treatment. Main Outcome Measures: Tumor size and overall survival. Results: Mice treated with adjuvant treatment or fusion cells alone did not show a statistical difference in tumor growth when compared with controls. In contrast, fusion cells with adjuvant treatment demonstrated a significant decrease in tumor size when compared with nontreated mice (P < .001). Treatment with fusion cells also resulted in increased survival in the pulmonary metastasis and subdermal tumor models. Conclusion: Immunotherapy with fused dendritictumor cell hybrids can significantly affect 3-day established sSCC VII tumor growth.

UR - http://www.scopus.com/inward/record.url?scp=45749102941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45749102941&partnerID=8YFLogxK

U2 - 10.1001/archotol.134.6.608

DO - 10.1001/archotol.134.6.608

M3 - Article

C2 - 18559727

AN - SCOPUS:45749102941

VL - 134

SP - 608

EP - 613

JO - JAMA Otolaryngology - Head and Neck Surgery

JF - JAMA Otolaryngology - Head and Neck Surgery

SN - 2168-6181

IS - 6

ER -